GO:0003108 negative regulation of the force of heart contraction by chemical signal: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003108 describes any chemical, hormonal, autocrine or paracrine signaling process that decreases the force of heart muscle contraction.
• It is a biological_process term that captures the negative inotropic effects of molecules such as endothelin-1, cardamonin and beta-adrenergic modulators.
• Key molecular players include Nrf2, MEK/ERK, protein kinase A and calmodulin-dependent kinase, which tune contractile protein expression and phosphorylation.
• Dysregulation of this process contributes to sepsis-induced myocardial dysfunction, heart failure and contractile failure under catecholamine stress.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate genes in this pathway.
• EDITGENE provides end-to-end cell model generation and CRISPR library screening to dissect negative inotropic signaling.
Description
GO:0003108, negative regulation of the force of heart contraction by chemical signal, is a Gene Ontology biological_process term that defines any process which decreases the force of heart muscle contraction mediated by chemical signaling, hormonal, autocrine or paracrine. This term is distinct from intrinsic contractile regulation because it specifically requires a chemical signal to trigger the reduction in contractile force. Researchers study this process to understand how circulating or locally released molecules suppress cardiac inotropy, a phenomenon central to sepsis, heart failure and drug-induced cardiotoxicity. Experimental evidence shows that lipopolysaccharide-induced myocardial contractile dysfunction can be attenuated by cardamonin through an Nrf2-regulated mechanism, directly linking chemical signaling to reduced contractile force. Similarly, endothelin-1 and isoprenaline co-stimulation causes contractile failure that is partially reversed by MEK inhibition, demonstrating the involvement of kinase signaling in this negative regulation. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression via protein kinase A and calmodulin-dependent kinase, providing a molecular link between adrenergic signals and contractile gene programs. Understanding GO:0003108 is therefore essential for identifying therapeutic targets that preserve cardiac function under stress.
negative regulation of the force of heart contraction by chemical signal At A Glance
| GO ID | GO:0003108 |
|---|---|
| GO term | negative regulation of the force of heart contraction by chemical signal |
| Ontology | biological_process |
| Synonym | negative regulation of the force of heart muscle contraction by chemical signal |
| Major function | Decreases the force of heart muscle contraction through chemical, hormonal, autocrine or paracrine signaling |
| Definition source | QuickGO |
| Related processes | Cardiac contractility, signal transduction, stress responses |
| Research relevance | Sepsis-induced myocardial dysfunction, heart failure, cardiotoxicity |
What Is GO:0003108?
In our own words, GO:0003108 encompasses all biological processes in which a chemical signal, whether hormonal, autocrine or paracrine, acts on heart muscle cells to reduce the force of contraction. This includes signaling cascades that alter calcium handling, myofilament sensitivity or contractile protein expression, ultimately decreasing cardiac inotropy.
Why Is negative regulation of the force of heart contraction by chemical signal Important in Cell Biology?
GO:0003108 is important because it provides a mechanistic framework for understanding how chemical signals suppress cardiac contractility, a process that is frequently dysregulated in acute and chronic heart diseases. For example, in sepsis, lipopolysaccharide triggers myocardial contractile dysfunction that can be mitigated by cardamonin via Nrf2, highlighting a druggable node within this term. In heart failure, sustained beta-adrenergic stimulation induces cardiac ankyrin repeat protein through protein kinase A and calmodulin-dependent kinase, which may contribute to maladaptive contractile regulation. Endothelin-1 and isoprenaline co-stimulation causes contractile failure that is partially reversed by MEK inhibition, underscoring the therapeutic potential of targeting kinase pathways within this process. Thus, dissecting GO:0003108 can reveal biomarkers and intervention points for cardiac dysfunction.
• Explains how chemical signals reduce cardiac contractile force in sepsis and heart failure.
• Links hormonal and paracrine signaling to contractile protein expression changes.
• Identifies Nrf2 as a protective regulator against lipopolysaccharide-induced contractile dysfunction.
• Highlights MEK/ERK signaling as a reversible node in contractile failure.
• Provides a framework for studying beta-adrenergic and calmodulin-dependent kinase effects on cardiac ankyrin repeat protein.
• Supports development of negative inotropic drugs with controlled cardiac effects.
• Aids in understanding cardiotoxicity of chemotherapeutic and inflammatory agents.
• Enables CRISPR-based causal validation of candidate genes in this pathway.
• Facilitates biomarker discovery for recurrent venous thromboembolism and cardiac stress.
• Guides personalized medicine approaches for heart failure patients.
What Happens During negative regulation of the force of heart contraction by chemical signal?
Chemical signal recognition and receptor activation
In simple terms: A chemical messenger binds to a receptor on heart muscle cells, starting the process that will weaken contraction.
The process begins when hormonal, autocrine or paracrine signals such as endothelin-1 or beta-adrenergic agonists bind to their cognate receptors on cardiomyocytes. This receptor activation triggers intracellular signaling cascades that ultimately reduce the force of contraction. For instance, endothelin-1 co-stimulation with isoprenaline leads to contractile failure in cardiac tissue, indicating that receptor-mediated signals converge on negative inotropic pathways.
Intracellular kinase cascade modulation
In simple terms: Enzymes inside the cell relay the signal, often involving kinases that can be blocked to reverse the effect.
Following receptor activation, kinases such as MEK, protein kinase A and calmodulin-dependent kinase are engaged. MEK inhibition partially reverses endothelin-1 and isoprenaline-induced contractile failure, demonstrating that this kinase pathway is functionally involved in reducing contractile force. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression through protein kinase A and calmodulin-dependent kinase, linking these kinases to downstream contractile gene regulation.
Transcriptional and post-transcriptional regulation of contractile genes
In simple terms: The signal changes which genes are turned on or off, altering the proteins that control contraction.
Chemical signals can modulate the expression of genes encoding contractile proteins and regulatory factors. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression via protein kinase A and calmodulin-dependent kinase, suggesting that transcriptional reprogramming contributes to negative regulation of contractile force. Additionally, Nrf2-regulated mechanisms protect against lipopolysaccharide-induced myocardial contractile dysfunction, indicating that antioxidant response pathways can counteract negative inotropic signaling.
Functional outcome: decreased contractile force
In simple terms: The end result is that the heart muscle contracts less forcefully.
The integration of these signaling events leads to a measurable decrease in the force of heart muscle contraction. In experimental models, lipopolysaccharide-induced myocardial contractile dysfunction is characterized by reduced contractile force, which can be attenuated by cardamonin through Nrf2. Similarly, endothelin-1 and isoprenaline co-stimulation causes contractile failure, and MEK inhibition partially restores contractile function. These findings confirm that GO:0003108 encompasses a functional reduction in cardiac inotropy driven by chemical signals.
Key Genes Involved in GO:0003108 negative regulation of the force of heart contraction by chemical signal
The following genes and proteins are experimentally implicated in the negative regulation of the force of heart contraction by chemical signal, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Nrf2 | Antioxidant response transcription factor | Protects against LPS-induced contractile dysfunction |
| MEK | Kinase in MAPK pathway | Inhibition reverses contractile failure |
| ERK | Downstream kinase of MEK | Mediates signaling in contractile failure |
| Protein kinase A | Phosphorylates cardiac proteins | Induced by beta-adrenergic stimulation |
| Calmodulin-dependent kinase | Calcium-dependent kinase | Induces cardiac ankyrin repeat protein |
| Cardiac ankyrin repeat protein | Transcriptional cofactor | Induced by beta-adrenergic signaling |
| Endothelin-1 | Vasoactive peptide | Causes contractile failure with isoprenaline |
| Isoprenaline | Beta-adrenergic agonist | Co-stimulation causes contractile failure |
| Cardamonin | Natural flavonoid | Protects against LPS-induced dysfunction |
| Beta-adrenergic receptor | G-protein coupled receptor | Mediates isoprenaline effects |
| Calmodulin | Calcium sensor | Activates calmodulin-dependent kinase |
| Ankyrin repeat domain | Protein interaction module | Part of cardiac ankyrin repeat protein |
| Nrf2 target genes | Antioxidant enzymes | Mediate protective effects |
| MAPK cascade | Signaling module | Involved in contractile failure |
| cAMP | Second messenger | Activates protein kinase A |
| Calcium channels | Ion channels | Regulate contractile force |
| Myofilament proteins | Contractile apparatus | Ultimate effectors of force reduction |
How Is negative regulation of the force of heart contraction by chemical signal Regulated?
The process of negative regulation of the force of heart contraction by chemical signal is itself regulated at multiple levels. Nrf2 acts as a counter-regulatory transcription factor that protects against lipopolysaccharide-induced myocardial contractile dysfunction, suggesting that antioxidant pathways can oppose negative inotropic signals. MEK/ERK signaling is a key node, as MEK inhibition partially reverses contractile failure induced by endothelin-1 and isoprenaline. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein via protein kinase A and calmodulin-dependent kinase, indicating that these kinases regulate downstream transcriptional responses. Additionally, gene expression changes in venous thromboembolism may share molecular signatures with cardiac stress pathways.
negative regulation of the force of heart contraction by chemical signal and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Nrf2 | Sepsis-induced myocardial dysfunction | Knockout and overexpression in cardiomyocytes |
| MEK | Contractile failure | Point mutation and knockout in cardiac cells |
| Protein kinase A | Beta-adrenergic contractile regulation | Knock-in of phospho-mutants |
| Calmodulin-dependent kinase | Cardiac ankyrin repeat protein induction | Knockout and overexpression |
| Endothelin-1 | Heart failure | Overexpression in cardiac tissue |
Sepsis-induced myocardial dysfunction
Lipopolysaccharide-induced myocardial contractile dysfunction is a hallmark of sepsis, and cardamonin protects against this dysfunction through an Nrf2-regulated mechanism. This directly links GO:0003108 to sepsis-related cardiac depression, where chemical signals reduce contractile force.
Heart failure and contractile failure
Endothelin-1 and isoprenaline co-stimulation causes contractile failure that is partially reversed by MEK inhibition, implicating this pathway in heart failure progression. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein, which may contribute to maladaptive remodeling.
Venous thromboembolism and cardiac biomarkers
Gene microarray analyses have identified potential biomarkers for single and recurrent venous thromboembolism, which may overlap with cardiac stress signaling pathways. Although not directly studied in GO:0003108, these findings suggest shared molecular mechanisms.
From negative regulation of the force of heart contraction by chemical signal-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Nrf2 mediate protection against LPS-induced contractile dysfunction? | Nrf2 knockout and overexpression cardiomyocytes |
| Is MEK required for endothelin-1/isoprenaline-induced contractile failure? | MEK point-mutation and knockout cells |
| Does protein kinase A phosphorylation regulate cardiac ankyrin repeat protein? | Knock-in of phospho-deficient mutants |
| Can calmodulin-dependent kinase inhibition prevent contractile dysfunction? | Knockout and tagged knock-in |
| What genes are downstream of beta-adrenergic signaling? | CRISPR library screening |
| Can cardamonin protect against contractile dysfunction? | Overexpression of Nrf2 targets |
How to Study the negative regulation of the force of heart contraction by chemical signal Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify transcriptional targets |
| Western blot | Protein phosphorylation and expression | Measure MEK/ERK and PKA activity |
| Traction force microscopy | Cardiomyocyte contractile force | Assess negative inotropic effects |
| Kinase activity assay | Enzymatic activity of kinases | Measure calmodulin-dependent kinase |
| CRISPR knockout screen | Gene function loss | Discover regulators of contractile force |
| CRISPR activation screen | Gene overexpression | Identify suppressors of contractility |
| Immunofluorescence | Protein localization | Visualize cardiac ankyrin repeat protein |
| qRT-PCR | mRNA levels | Validate gene expression changes |
Transcriptomic profiling
RNA-seq and gene microarray analyses can identify global changes in gene expression during negative regulation of contractile force. For example, gene microarray analyses identified biomarkers for venous thromboembolism, demonstrating the utility of transcriptomics in cardiac-related signaling. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein, which can be detected by RNA-seq.
Protein phosphorylation and signaling assays
Western blotting and kinase activity assays can measure MEK/ERK phosphorylation and protein kinase A activity. MEK inhibition partially reverses contractile failure, and this can be monitored by phospho-specific antibodies. Calmodulin-dependent kinase activity can be assessed using in vitro kinase assays.
Functional contractility measurements
Cardiomyocyte contractility can be measured using traction force microscopy or edge detection. Lipopolysaccharide-induced contractile dysfunction and its reversal by cardamonin can be quantified. Endothelin-1 and isoprenaline co-stimulation causes contractile failure that is partially reversed by MEK inhibition, providing a functional readout.
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes that regulate negative inotropic signaling. For instance, screening for modifiers of beta-adrenergic response could reveal novel regulators of cardiac ankyrin repeat protein expression. Such screens are powerful for unbiased discovery in GO:0003108.
How CRISPR Can Be Used to Study GO:0003108 negative regulation of the force of heart contraction by chemical signal
Knockout
CRISPR knockout of candidate genes such as Nrf2 or MEK can test their requirement in negative regulation of contractile force. For example, Nrf2 knockout would abolish the protective effect of cardamonin against LPS-induced dysfunction. MEK knockout would prevent the reversal of contractile failure by MEK inhibition.
Point Mutation
Introducing point mutations in kinase domains or phosphorylation sites can dissect signaling mechanisms. For instance, mutating the catalytic site of MEK would block its activity and mimic MEK inhibition. Phospho-deficient mutants of protein kinase A substrates can reveal their role in cardiac ankyrin repeat protein induction.
Knock-in
Knock-in of tagged or reporter alleles allows real-time monitoring of gene expression and localization. A cardiac ankyrin repeat protein reporter knock-in would enable tracking of beta-adrenergic-induced expression. Tagged Nrf2 knock-in would facilitate chromatin immunoprecipitation studies.
Overexpression
CRISPR activation or cDNA overexpression can test gain-of-function effects. Overexpressing Nrf2 targets could protect against contractile dysfunction. Overexpressing cardiac ankyrin repeat protein might mimic beta-adrenergic effects on contractility.
How EDITGENE Supports negative regulation of the force of heart contraction by chemical signal Research
Researchers studying negative regulation of the force of heart contraction by chemical signal-related genes often need to determine whether a candidate gene is causally involved in reducing cardiac contractility or is merely a bystander. EDITGENE provides the necessary CRISPR tools and services to establish causality through precise genome editing.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of the force of heart contraction by chemical signal research.
Frequently Asked Questions About negative regulation of the force of heart contraction by chemical signal
What is GO:0003108?
GO:0003108 is a Gene Ontology biological_process term for any process that decreases the force of heart muscle contraction mediated by chemical, hormonal, autocrine or paracrine signaling.
What genes are involved in negative regulation of the force of heart contraction by chemical signal?
Key genes include Nrf2, MEK, ERK, protein kinase A, calmodulin-dependent kinase and cardiac ankyrin repeat protein.
How does endothelin-1 cause contractile failure?
Endothelin-1 co-stimulation with isoprenaline causes contractile failure that is partially reversed by MEK inhibition, indicating kinase involvement.
What is the role of Nrf2 in cardiac contractile dysfunction?
Nrf2 mediates protection against lipopolysaccharide-induced myocardial contractile dysfunction by cardamonin.
How does beta-adrenergic signaling affect cardiac ankyrin repeat protein?
Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression via protein kinase A and calmodulin-dependent kinase.
What diseases are associated with GO:0003108?
Sepsis-induced myocardial dysfunction, heart failure and contractile failure are associated with this process.
How can CRISPR help study negative regulation of heart contraction?
CRISPR knockout, point mutation, knock-in and overexpression can test causal roles of genes like Nrf2 and MEK in contractile regulation.
What methods measure the force of heart contraction?
Traction force microscopy and edge detection are used to measure cardiomyocyte contractility.
What is the role of MEK in contractile failure?
MEK inhibition partially reverses endothelin-1 and isoprenaline-induced contractile failure.
How does cardamonin protect against myocardial dysfunction?
Cardamonin protects through an Nrf2-regulated mechanism against lipopolysaccharide-induced contractile dysfunction.
Conclusion
GO:0003108, negative regulation of the force of heart contraction by chemical signal, is a critical biological process that integrates hormonal, autocrine and paracrine signals to reduce cardiac contractility. Experimental evidence implicates Nrf2, MEK/ERK, protein kinase A and calmodulin-dependent kinase in this process, with direct relevance to sepsis, heart failure and contractile failure. Understanding these mechanisms offers therapeutic opportunities to preserve cardiac function under stress. CRISPR-based models from EDITGENE can accelerate the discovery of causal genes and drug targets within this pathway.
References
- 1. Tan Y et al.. 2021. Cardamonin protects against lipopolysaccharide-induced myocardial contractile dysfunction in mice through Nrf2-regulated mechanism.. Acta Pharmacol Sin 42(3):404-413 PMID: 32317756
- 2. Zhou W et al.. 2015. Gene microarray analyses for potential biomarkers of single and recurrent venous thromboembolism.. Mol Med Rep 12(5):7358-66 PMID: 26397997
- 3. Münzel F et al.. 2005. Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition.. Cardiovasc Res 68(3):464-74 PMID: 16040022
- 4. Zolk O et al.. 2003. Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression: involvement of protein kinase A and calmodulin-dependent kinase.. Cardiovasc Res 59(3):563-72 PMID: 14499857
